Better Health for All

Medpace's core mission is to accelerate the global development of safe and effective medical therapeutics, connecting lifesaving innovations with patients.

The company focuses on critical areas such as oncology, hematology (conducting over 250 trials), and mental health, aiming to improve treatments for conditions like MDD, schizophrenia, and bipolar disorder. Medpace's services are entirely dedicated to health improvement, and there is no evidence of revenue from products or activities with negative health outcomes. The company works with highly confidential client data and medical information, prohibiting disclosure outside the company and limiting internal access to a need-to-know basis. Medpace is committed to protecting individual privacy in personal data processing and expects vendors to comply with data privacy laws. The company emphasizes an uncompromising commitment to clinical research and the highest ethical standards, adhering to policies, standard operating procedures, and applicable regulatory guidelines. Medpace aims to increase patient diversity in clinical trials, considering ethnic groups, race, older adults, LGBTQ, and rural community access, and partners with communities to connect with patients. However, specific quantitative data on the percentage of vulnerable populations reached is not provided. The company's Code of Business Conduct and Ethics requires full, fair, accurate, timely, and understandable disclosures in financial reports and public communications, prohibiting misrepresentation or omission of material facts. Medpace promotes diversity, equity, and inclusion (DEI) in clinical trials through recruitment and retention strategies, evaluates protocols with an inclusivity lens, and supports community health fairs. The company provides training to CRO staff on recruitment objectives and cultural competency for site staff, and employs global, in-house medical experts.

Fair Trade & Ethical Sourcing

No specific, concrete data points were found in the provided articles regarding Medpace Holdings, Inc.'s fair trade and ethical sourcing practices.

The articles explicitly state that they do not contain information relevant to the defined KPIs, such as fair-trade certifications, audit frequency, forced/child labor incidents, traceability, remediation speed, ethical clause coverage, materials risk, or supplier diversity spend. Therefore, no assessment can be made against the defined KPIs.

Honest & Fair Business

Medpace has a formal whistleblower protection policy with an anonymous hotline and dedicated email/phone, and reporting mechanisms to the Corporate Compliance Officer or Audit Committee.

Anonymous reporting is accepted, but the evidence does not specify independent investigation processes. The company also has an anti-corruption policy covering all employees and third parties, addressing the FCPA and UK Anti-Bribery Act, with annual training required for all employees. However, the effectiveness of this training is not publicly measured.

No War, No Weapons

Medpace Holdings, Inc. made a donation of over $2.5 million to Matthew 25 Ministries for humanitarian relief efforts in Ukraine.

However, the provided articles, including the company's corporate responsibility reports and ethics statements, explicitly state that no information is available regarding revenue from arms contracts, dual-use technology, sales to embargoed regimes, conflict divestment, board oversight of defense activities, export compliance, lobbying, humanitarian procurement, human rights due diligence, Arms Trade Treaty compliance, AI military safeguards, UN Guiding Principles alignment, dual-use screening, surveillance transparency, ethical red lines, zero exposure to controversial weapons, war-risk audits, annual conflict partner reviews, defense divestment, conflict minerals, peace tech investment, or conflict zone procurement. While a humanitarian donation was made, the company's total revenue is not provided, preventing the calculation of the proportion allocated to peacebuilding investment. Therefore, no KPIs can be scored based on the available evidence.

Zero Waste & Sustainable Products

Medpace's corporate responsibility reports for 2019-2020 and 2021-2022 indicate no specific waste disposal violations, fines, or regulatory actions were detailed.

The 2023-2024 report also does not contain any such data. For all other KPIs related to Zero Waste & Sustainable Products, the reports explicitly state a lack of specific quantitative data, including waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management performance, product durability, repairability scores, waste audit frequency, zero-waste certifications, material efficiency, packaging-to-product ratios, waste reduction targets, supplier waste requirements, or customer waste education.